An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

Inclusion Criteria: * Participants with a current diagnosis of schizophrenia, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria, who completed the open-label extension Study 248 (completed Study 248 study completion visit, Week 52). * Participants who, in the investigator's judgment, may benefit from continued participation in an aripiprazole IM Depot study. * The baseline visit for Study 270 (which is the Week 52 visit of Study 248) and the first injection for Study 270 must occur within 4 weeks (which was defined as 28 \[-2/+10\] days) of the last injection in Study 248. * Participants who are able to provide written informed consent and/or consent obtained from a legally acceptable representative (as required by an Independent Review Board/Independent Ethics Committee (IRB/IEC), prior to the initiation of any protocol-required procedures. * Participants able to understand the nature of the study and follow protocol requirements and who can read and understand the written word in order to complete patient-reported outcomes measures. * Outpatient status. Exclusion Criteria: * Participants with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic, or other cognitive disorders. * Participants with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder. * Participants who currently meet DSM-IV-TR criteria for substance dependence, including alcohol and benzodiazepines, but excluding caffeine and nicotine. * Participants with a significant risk of violent behavior or a significant risk of committing suicide based on the investigator's judgment. * Participants who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones. * Participants with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia at screening. * Electroconvulsive therapy within 180 days prior to entry. * Any participant who requires or may need any other antipsychotic medications during the course of the study. * Aripiprazole IM Depot (including generic formulation) is commercially available in the participant's country. * Other protocol specific inclusion/exclusion criteria may apply.